Myelodysplastic syndrome.

Indian Journal of Pediatrics
V TilakJ Shukla

Abstract

Pediatric myelodysplastic syndrome (MDS), though rare, constitutes a distinct entity quite different from adult MDS. They have unique clinical features, aggressive clinical course with an overall mean survival of only 9.9 months. A pediatric approach to the WHO classification has become necessary since the WHO classification of MDS has failed to address the uniqueness of pediatric MDS. A new prognostic system also needs to be evolved since the international prognostic system has limited prognostic impact in children. Intensive chemotherapy such as the one used in de novo-acute myeloid leukemia (AML) leads to complete remission in some children and this may be the treatment of choice in pediatric MDS.

References

Oct 1, 1992·British Journal of Haematology·M A TuncerG J Mufti
Jan 1, 1991·Acta Paediatrica Hungarica·H Gadner
Dec 1, 1987·Seminars in Oncology·G J TricotR Hoffman
May 1, 1985·British Journal of Haematology·E R van WeringP M Theunissen
Oct 1, 1996·British Medical Bulletin·S J Passmore, I M Hann
Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F LocatelliM Zimmermann
Nov 30, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N L HarrisC D Bloomfield
Oct 30, 2001·Leukemia·H SasakiUNKNOWN MDS Committee of the Japanese Society of Pediatric Hematology, Japan
Jul 27, 2002·Journal of Pediatric Hematology/oncology·Karen MandelMelvin H Freedman
Jan 18, 2005·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Dale Halsey LeaRosemarie Smith

❮ Previous
Next ❯

Citations

Sep 3, 2011·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Vineeta Gupta, Baldev Bhatia

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.